AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8772864 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial exchange blood transfusion with normal saline
Number of subjects: 30
Study 8772864 — intervention group
Group type: COMPARATOR
Intervention: Partial exchange blood transfusion with plasma
Number of subjects: 30
Study 2119678 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 9
Study 2119678 — intervention group
Group type: COMPARATOR
Intervention: Sitting
Number of subjects: 9
Study 7204956 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80
Study 7204956 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 80
Study 31765976 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mgI/kg
Number of subjects: 204
Study 31765976 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mgI/kg
Number of subjects: 204
Study 31765976 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mgI/kg
Number of subjects: 204
Study 31292311 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 20
Study 31292311 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 20
Study 28693594 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative infusion regime with sodium glycerophosphate and Jonosteril®
Number of subjects: 0
Study 28693594 — intervention group
Group type: COMPARATOR
Intervention: Jonosteril® (comparator) alone
Number of subjects: 0
Study 25294611 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD, inhaled)
Number of subjects: 80
Study 25294611 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 80
Study 25294611 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (BUD/FM, inhaled)
Number of subjects: 80
Study 25294611 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol tablet (PT)
Number of subjects: 80
Study 25294611 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 80
Study 24848284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100‐250 mg bid)
Number of subjects: 318
Study 24848284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 22222146 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 0
Study 22222146 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 19782476 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nasal testosterone dose
Number of subjects: 0
Study 19782476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17376106 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine at age 6 years
Number of subjects: 1132
Study 17376106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-type headache
Number of subjects: 1132
Study 17376106 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent symptoms with headache
Number of subjects: 1132
Study 15608429 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11888760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 35
Study 11888760 — intervention group
Group type: COMPARATOR
Intervention: Warm blood cardioplegia
Number of subjects: 35
Study 10362952 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention for breathlessness
Number of subjects: 52
Study 10362952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 52
Study 7605760 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain 'alkalinized' 0.5% bupivacaine
Number of subjects: 30
Study 7605760 — intervention group
Group type: COMPARATOR
Intervention: Plain 'non‐alkalinized' 0.5% bupivacaine
Number of subjects: 30
Study 2136968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isradipine (0.01 mg/kg, n = 16)
Number of subjects: 24
Study 2136968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 24
Study 7084649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 45
Study 7084649 — intervention group
Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 45
Study 30657013 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX (torsionally flexible shoe sole)
Number of subjects: 8
Study 30657013 — intervention group
Group type: COMPARATOR
Intervention: STIFF (relatively stiffer shoe sole)
Number of subjects: 8
Study 30657013 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX
Number of subjects: 8
Study 30657013 — intervention group
Group type: COMPARATOR
Intervention: STIFF
Number of subjects: 8
Study 30657013 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX responders
Number of subjects: 8
Study 27400891 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound-guided femoral nerve block
Number of subjects: 60
Study 27400891 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia
Number of subjects: 60
Study 27400891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 25012957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered brief health education intervention (3-min telephone + 3-min face-to-face)
Number of subjects: 2517
Study 25012957 — intervention group
Group type: COMPARATOR
Intervention: Standard care (health education leaflets and/or video show)
Number of subjects: 2517
Study 23901266 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) program
Number of subjects: 58
Study 23901266 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 58
Study 21134105 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 1802
Study 21134105 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1802
Study 19817721 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 340
Study 19134041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol rinse before luting with All Bond 2 adhesive system
Number of subjects: 0
Study 19134041 — intervention group
Group type: COMPARATOR
Intervention: Control application of All Bond 2 adhesive system without ethanol rinse
Number of subjects: 0
Study 19134041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol rinse before luting with One Step Plus adhesive system
Number of subjects: 0
Study 19134041 — intervention group
Group type: COMPARATOR
Intervention: Control application of One Step Plus adhesive system without ethanol rinse
Number of subjects: 0
Study 16002021 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement-based therapy (RBT)
Number of subjects: 130
Study 16002021 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 12468789 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 22
Study 12468789 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 22
Study 9395384 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily primaquine
Number of subjects: 0
Study 9395384 — intervention group
Group type: COMPARATOR
Intervention: Weekly chloroquine
Number of subjects: 0
Study 9395384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unvaccinated control)
Number of subjects: 0
Study 7966041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoconazole, 400 mg daily for 14 days
Number of subjects: 151
Study 7966041 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole vaginal suppositories, 100 mg daily for 7 days
Number of subjects: 151
Study 7966041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 151
Study 7966041 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole
Number of subjects: 151
Study 7966041 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic ketoconazole
Number of subjects: 151
Study 3311440 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine plus sulfadoxine-pyrimethamine (Fansimef)
Number of subjects: 100
Study 3311440 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (Fansidar)
Number of subjects: 100
Study 12418395 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of beta-interferon used every other day
Number of subjects: 0
Study 12418395 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon
Number of subjects: 0
Study 27884047 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (weight gain prevention)
Number of subjects: 272
Study 27884047 — intervention group
Group type: COMPARATOR
Intervention: Attention control (oral health)
Number of subjects: 272
Study 27703286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.2 mg/kg)
Number of subjects: 60
Study 27703286 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 60
Study 24948466 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG with or without isoniazid (INH)
Number of subjects: 822
Study 24948466 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 822
Study 22325844 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-weekly intensive phase therapy
Number of subjects: 750
Study 22325844 — intervention group
Group type: COMPARATOR
Intervention: Daily intensive phase therapy
Number of subjects: 750
Study 22325844 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 750
Study 22325844 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected participants
Number of subjects: 750
Study 20375228 — intervention group
Group type: EXPERIMENTAL
Intervention: Read It Again! (RIA) curriculum implemented by teachers
Number of subjects: 20
Study 20375228 — intervention group
Group type: COMPARATOR
Intervention: Control group (teachers not implementing RIA)
Number of subjects: 20
Study 18604321 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard nutritional supplement
Number of subjects: 537
Study 18604321 — intervention group
Group type: COMPARATOR
Intervention: Hospital diet according to needs and pathology
Number of subjects: 537
Study 16002932 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg IV, q12h)
Number of subjects: 398
Study 16002932 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1g IV, q8h) + Ofloxacin (200 mg IV, q12h)
Number of subjects: 398
Study 12442932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.05 microg kg(‐1) i.v. (Group A, n = 15)
Number of subjects: 32
Study 12442932 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 2 microg kg(‐1) i.v. (Group B, n = 17)
Number of subjects: 32
Study 10604046 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil and caraway oil combination preparation (PCC, Enteroplant)
Number of subjects: 120
Study 10604046 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (CIS, CAS 81098‐60‐4)
Number of subjects: 120
Study 7791267 — intervention group
Group type: EXPERIMENTAL
Intervention: MND-21 (2.7 g EPA‐E) daily for 12 weeks
Number of subjects: 10
Study 7791267 — intervention group
Group type: EXPERIMENTAL
Intervention: MND-21 (2.7 g EPA‐E) for 4 weeks
Number of subjects: 10
Study 7791267 — intervention group
Group type: COMPARATOR
Intervention: Control (no EPA‐E)
Number of subjects: 10
Study 7791267 — intervention group
Group type: EXPERIMENTAL
Intervention: MND-21 (2.7 g EPA‐E) for 2 months
Number of subjects: 10
Study 1942284 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 150
Study 1942284 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 150
Study 1942284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedimentation rate
Number of subjects: 150
Study 1942284 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedimentation rate elevated 20 mm/hour
Number of subjects: 150
Study 6820891 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for 3 consecutive days before surgery, repeated every fortnight for one year after surgery)
Number of subjects: 342
Study 6820891 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (20 mg day 0, 10 mg day 1, one shot i.v.) and 5-FU (150 mg/day, p.o.)
Number of subjects: 342
Study 31030167 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts (40 g/day for 4 weeks)
Number of subjects: 15
Study 28122805 — intervention group
Group type: EXPERIMENTAL
Intervention: Double kissing crush
Number of subjects: 370
Study 28122805 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 370
Study 28122805 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex bifurcation lesions
Number of subjects: 370
Study 28122805 — intervention group
Group type: COMPARATOR
Intervention: Provisional stenting in complex bifurcation
Number of subjects: 370
Study 28122805 — intervention group
Group type: EXPERIMENTAL
Intervention: Final kissing balloon inflation
Number of subjects: 370
Study 27094558 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 48
Study 27094558 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MET)
Number of subjects: 48
Study 27094558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24452849 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 50-100 mg/day
Number of subjects: 19
Study 24452849 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin-free period
Number of subjects: 19
Study 22081052 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (7.5 g/day) with a standard dose of RPZ (10 mg/day)
Number of subjects: 104
Study 22081052 — intervention group
Group type: COMPARATOR
Intervention: Double dose of RPZ (20 mg/day)
Number of subjects: 104
Study 22081052 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito group (specifically male NERD patients)
Number of subjects: 104
Study 22081052 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito group (NERD patients with low BMI)
Number of subjects: 104
Study 19410209 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care (CenteringPregnancy model)
Number of subjects: 322
Study 19410209 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 322
Study 17123673 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm Bier's block
Number of subjects: 30
Study 17123673 — intervention group
Group type: COMPARATOR
Intervention: Conventional Bier's block
Number of subjects: 30
Study 16360449 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic massage
Number of subjects: 51
Study 11465651 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg/day
Number of subjects: 88
Study 11465651 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + HCTZ 12.5 mg/day
Number of subjects: 88
Study 11465651 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/day
Number of subjects: 88
Study 11465651 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg + Benazepril 20 mg/day
Number of subjects: 88
Study 15010720 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 7917736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium infusion with prior administration of suxamethonium
Number of subjects: 20
Study 7917736 — intervention group
Group type: COMPARATOR
Intervention: Atracurium infusion without prior administration of suxamethonium
Number of subjects: 20
Study 3294318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic/steroid ear drops
Number of subjects: 163
Study 3294318 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 163
Study 3294318 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy (antibiotic/steroid ear drops)
Number of subjects: 163
Study 3294318 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (antibiotic used in active therapy)
Number of subjects: 163
Study 3294318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 163
Study 31124721 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequately Controlled (AC) hypoparathyroidism
Number of subjects: 614
Study 31124721 — intervention group
Group type: COMPARATOR
Intervention: Not Adequately Controlled (NAC) hypoparathyroidism
Number of subjects: 614
Study 28810284 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid therapy (initial dose of 80 mg prednisolone for 2 weeks, tapered over 3 to 4 months)
Number of subjects: 3
Study 28810284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 3
Study 25724322 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention comprising twice-weekly exercise classes of one hour duration for 4 months, including aerobic exercise at moderate intensity and resistance exercise using weight vests, weight belts, and dumbbells.
Number of subjects: 0
Study 25724322 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised, independent exercise following the supervised intervention.
Number of subjects: 0
Study 23543804 — intervention group
Group type: EXPERIMENTAL
Intervention: NSF-3 (one tablet at bedtime for two weeks)
Number of subjects: 91
Study 23543804 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (one 10 mg tablet at bedtime for two weeks)
Number of subjects: 91
Study 21903982 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (target international normalized ratio 2 to 3)
Number of subjects: 1936
Study 21903982 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg) plus fixed, low-dose warfarin
Number of subjects: 1936
Study 19562573 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 883
Study 19562573 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 883
Study 17097957 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) at 0.15 mg/kg/d
Number of subjects: 26
Study 15337012 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer TMLR
Number of subjects: 30
Study 15337012 — intervention group
Group type: COMPARATOR
Intervention: Maximal medication (Control)
Number of subjects: 30
Study 10891905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a
Number of subjects: 97
Study 10891905 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (according to the first question of the SF-36)
Number of subjects: 97
Study 8826889 — intervention group
Group type: EXPERIMENTAL
Intervention: rh alpha‐2b‐interferon (IFN) at a dose of 3 mU three times per week, given concurrently with VAD (VIC)
Number of subjects: 72
Study 8826889 — intervention group
Group type: EXPERIMENTAL
Intervention: rh alpha‐2b‐interferon (IFN) at a dose of 3 mU three times per week, given as maintenance after completion of VAD (VIF)
Number of subjects: 72
Study 8826889 — intervention group
Group type: COMPARATOR
Intervention: VAD alone (historic control group)
Number of subjects: 72
Study 1533166 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with continuous high TEA using 0.125% bupivacaine plus sufentanil (0.05 mL/cm body length/hr)
Number of subjects: 54
Study 1533166 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with IV administration of nicomorphine (0.1 mg/kg every 6 hours)
Number of subjects: 54
Study 3909977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl clofibrate (100 mg/kg, single oral dose between 24th and 48th hour of life)
Number of subjects: 89
Study 3909977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 30255449 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT/magnetic field
Number of subjects: 21
Study 30255449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 21
Study 28514601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg subcutaneously every 4 weeks for 52 weeks)
Number of subjects: 136
Study 28514601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 26289355 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg MAS‐XR
Number of subjects: 52
Study 26289355 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg MAS‐XR
Number of subjects: 52
Study 26289355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 24121755 — intervention group
Group type: EXPERIMENTAL
Intervention: abacavir/lamivudine
Number of subjects: 244
Study 24121755 — intervention group
Group type: COMPARATOR
Intervention: tenofovir-DF/emtricitabine with efavirenz or atazanavir/ritonavir
Number of subjects: 244
Study 24121755 — intervention group
Group type: EXPERIMENTAL
Intervention: time-updated values of IL-6, sTNFR-I and II, and sICAM-1
Number of subjects: 244
Study 24121755 — intervention group
Group type: EXPERIMENTAL
Intervention: time-updated tumor necrosis factor α
Number of subjects: 244
Study 23073140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate (1 mg - 100 mg single oral doses)
Number of subjects: 33
Study 19038525 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling (IDC) + Group Drug Counseling (GDC) for 3 months
Number of subjects: 41
Study 19038525 — intervention group
Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC) alone for 3 months
Number of subjects: 41
Study 17235504 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg subcutaneously after R-CHOP-14
Number of subjects: 10
Study 15387326 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (14, 28, or 56 g) twice daily for 7 days
Number of subjects: 9
Study 12044300 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐n1 [INS] (two tablets of 200 IU each, given sublingually once daily for eight months)
Number of subjects: 0
Study 12044300 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐n1 [INS]
Number of subjects: 0
Study 12044300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10350219 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP recruitment strategies
Number of subjects: 1041
Study 8983878 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide diet or oral prednisolone
Number of subjects: 30
Study 8983878 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 1661630 — intervention group
Group type: EXPERIMENTAL
Intervention: otilonium bromide (OB) 40mg tid and normal diet (10‐15 g of fibers)
Number of subjects: 114